Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

MLA

Portacci, Andrea, et al. “Real-World Characteristics of ‘Super-Responders’ to Mepolizumab and Benralizumab in Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis.” ERJ Open Research, vol. 9, no. 5, Oct. 2023. EBSCOhost, https://doi.org/10.1183/23120541.00419-2023.

APA

Portacci, A., Campisi, R., Buonamico, E., Nolasco, S., Pelaia, C., Crimi, N., Benfante, A., Triggiani, M., Spadaro, G., Caiaffa, M. F., Scioscia, G., Detoraki, A., Valenti, G., Papia, F., Tomasello, A., Scichilone, N., Pelaia, G., Crimi, C., & Carpagnano, G. E. (2023). Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. ERJ Open Research, 9(5). https://doi.org/10.1183/23120541.00419-2023

Chicago

Portacci, Andrea, Raffaele Campisi, Enrico Buonamico, Santi Nolasco, Corrado Pelaia, Nunzio Crimi, Alida Benfante, et al. 2023. “Real-World Characteristics of ‘Super-Responders’ to Mepolizumab and Benralizumab in Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis.” ERJ Open Research 9 (5). doi:10.1183/23120541.00419-2023.